Liu Tao, Tian Manman, Wang Jiayue, Tian Xiangge, Liu Jihong, Feng Lei, Ma Xiaochi, Cui Jingnan
State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.
Academy of Integrative Medicine, The National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Spectrochim Acta A Mol Biomol Spectrosc. 2021 Apr 15;251:119362. doi: 10.1016/j.saa.2020.119362. Epub 2021 Jan 22.
Drug-induced liver injury (DILI) has become a common adverse effect in routine clinical practice, which would further cause the disorder of enzymatic system that respond to multiple pathological progresses. Leucine aminopeptidase (LAP) is regarded as a biomarker in the early course of various liver diseases, in this work, a fluorescent probe NCPL was designed and synthesized for the detecting of LAP. NCPL possessed excellent properties including high selectivity, sensitivity and affinity toward LAP, it could real-time image the LAP activity in living cells and tissues. Additionally, the upregulation of LAP under the APAP-induced liver injury model was also illustrated by NCPL. In conclusion, NCPL as a novel tool could be used for the detection of LAP and monitoring liver function in clinic.
药物性肝损伤（DILI）已成为常规临床实践中常见的不良反应，这会进一步导致应对多种病理进展的酶系统紊乱。亮氨酸氨肽酶（LAP）被视为各种肝脏疾病早期过程中的生物标志物，在本研究中，设计并合成了一种用于检测LAP的荧光探针NCPL。NCPL对LAP具有高选择性、高灵敏度和高亲和力等优异性能，能够对活细胞和组织中的LAP活性进行实时成像。此外，NCPL还证实了对乙酰氨基酚（APAP）诱导的肝损伤模型中LAP的上调。总之，NCPL作为一种新型工具可用于临床检测LAP和监测肝功能。
